Lobbying Filing Details

Total Spending

$520,000

Activities

5

Lobbyists

4

Gov't Entities

10

Filing Information
Filing UUID:
62aba60d-46b6-46da-a1cb-8a89083dfdaa
Type:
Q2 - 2nd Quarter - Report
Period:
2022 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 19, 2022 at 10:49 PM
Income:
$0
Expenses:
$520,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Samantha Ventimiglia
Registrant
VERTEX PHARMACEUTICALS INCORPORATED

Global biotechnology company

Boston, Massachusetts
Client
VERTEX PHARMACEUTICALS INCORPORATED
Massachusetts, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."

Lobbyists (4)
  • SAMANTHA VENTIMIGLIA
  • SCOTT BARNES
  • MATTHEW O SCHUMAKER
  • KWAMME ANDERSON
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.

Lobbyists (4)
  • SAMANTHA VENTIMIGLIA
  • SCOTT BARNES
  • MATTHEW O SCHUMAKER
  • KWAMME ANDERSON
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medical/Disease Research/Clinical Labs

General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."

Lobbyists (4)
  • SAMANTHA VENTIMIGLIA
  • SCOTT BARNES
  • MATTHEW O SCHUMAKER
  • KWAMME ANDERSON
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Medicare/Medicaid

Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).

Lobbyists (4)
  • SAMANTHA VENTIMIGLIA
  • SCOTT BARNES
  • MATTHEW O SCHUMAKER
  • KWAMME ANDERSON
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 5
Taxation/Internal Revenue Code

Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."

Lobbyists (4)
  • SAMANTHA VENTIMIGLIA
  • SCOTT BARNES
  • MATTHEW O SCHUMAKER
  • KWAMME ANDERSON
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.